Bank Of America Corp Myovant Sciences Ltd. Transaction History

Bank Of America Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	BUY	$24.03 - $27.02 $5.33 Million - $5.99 Million	221,690 Added 145.91%	373,629 $10.1 Million
Q3 2022 Nov 14, 2022	BUY	$11.6 - $20.44 $1.29 Million - $2.28 Million	111,367 Added 274.49%	151,939 $2.73 Million
Q2 2022 Aug 12, 2022	SELL	$7.78 - $14.69 $1.15 Million - $2.16 Million	-147,276 Reduced 78.4%	40,572 $504,000
Q1 2022 May 16, 2022	BUY	$11.38 - $16.4 $385,725 - $555,878	33,895 Added 22.02%	187,848 $2.5 Million
Q4 2021 Feb 08, 2022	BUY	$14.31 - $23.87 $2.06 Million - $3.43 Million	143,725 Added 1405.21%	153,953 $2.4 Million
Q3 2021 Nov 15, 2021	BUY	$18.94 - $26.99 $10,549 - $15,033	557 Added 5.76%	10,228 $230,000
Q2 2021 Sep 13, 2021	BUY	$17.07 - $24.56 $165,083 - $237,519	9,671 New	9,671 $220,000

61.3K

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.